AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16714386
Drug: Recombinant methionyl
RxNorm normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant methionyl human leptin (r-metHuLeptin) administered during fasting
Trial: 16714386
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered during fasting
Trial: 11706112
Drug: Levodopa plus
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa plus dopa decarboxylase inhibitor
Trial: 10567624
Drug: Inhaled ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ozone (200 ppb)
Trial: 8704426
Drug: Zhuchun Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhuchun Pill (ZCP)
Trial: 2490739
Drug: Preparation the
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation the afternoon before surgery
Trial: 2490739
Drug: Preparation the
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation the morning of surgery
Trial: 778433
Drug: Coenzyme Q7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme Q7 intravenous injection (50 to 100 mg daily for 3 to 35 days)
Trial: 778433
Drug: Coenzyme Q7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme Q7 oral administration (60 mg daily for 14 to 196 days)
Trial: 778433
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 oral administration (30 mg daily for 7 to 182 days)
Trial: 31331568
Drug: Almond sachet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond sachet (40 g/day for 20 days)
Trial: 29173737
Drug: Positive Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Family Interaction Therapy (PFIT)
Trial: 21258153
Drug: AZD3480 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3480 5 mg
Trial: 21258153
Drug: AZD3480 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3480 20 mg
Trial: 21258153
Drug: AZD3480 35/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3480 35/100 mg
Trial: 21258153
Drug: Donepezil 10
RxNorm normalized name: donepezil 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg (active comparator)
Trial: 16391376
Drug: Eptifibatide (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (180 micro/kg bolus x 2, 10 minutes apart, then 2 micro/kg/min infusion over 18 hours)
Trial: 16391376
Drug: Low-dose unfractionated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose unfractionated heparin (60 Units per kg, target ACT 200-250 sec)
Trial: 16391376
Drug: High-dose unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose unfractionated heparin (100 Units per kg, target ACT 300-400 sec)
Trial: 8501499
Drug: Pilocarpine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (2.5 mg, 5.0 mg, and 10.0 mg tablets over 12 weeks)
Trial: 3567973
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (ara-C) 3 g/m2 infused over 2 hours
Trial: 3567973
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (ara-C) 3 g/m2 infused over 2 hours with amsacrine (m-AMSA) 30 mg/m2 infused over 1 hour
Trial: 30003598
Drug: 4.0 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 × 6 mm implants (test group; N = 108)
Trial: 30003598
Drug: 4.0 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 × 11 mm implants (control group; N = 101)
Trial: 30003598
Drug: 4.0 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 × 6 mm implants (test group)
Trial: 30003598
Drug: 4.0 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 × 11 mm implants (control group)
Trial: 18396390
Drug: Liquisolid tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquisolid tablet formulation of famotidine
Trial: 18396390
Drug: Marketed famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marketed famotidine tablets
Trial: 15988707
Drug: Intralipid (20%)
RxNorm normalized name: soybean oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid (20%) with heparin sodium
Trial: 15988707
Drug: Saline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline and heparin sodium
Trial: 10232714
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg x kg(‐1) i.v. (Group P)
Trial: 1856488
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell combined with cholera B subunit vaccine (WC/BS)
Trial: 1856488
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell only vaccine (WC)
Trial: 23775924
Drug: Cognitive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive treatment (control group)
Trial: 21984428
Drug: Activated magnetic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated magnetic resonance therapy
Trial: 21984428
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no magnetic resonance therapy)
Trial: 20345019
Drug: Oral candida
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral candida
Trial: 17366745
Drug: Tablet B7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet B7 (once daily sustained release tablets of aceclofenac)
Trial: 17366745
Drug: Tablet B7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet B7
Trial: 15117041
Drug: Magnesium glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium glycine (Mg glycine)
Trial: 15117041
Drug: Potassium magnesium
RxNorm normalized name: POTASSIUM MAGNESIUM SULFATE
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium magnesium citrate (K Mg citrate)
Trial: 2889522
Drug: OK-432 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OK-432 treatment group
Trial: 27740639
Drug: Short dental
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short dental implants (5.5 or 7 mm)
Trial: 27740639
Drug: Standard dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dental implants (10 or 12 mm)
Trial: 20346518
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 2 weeks followed by Escitalopram 10 mg daily for 12 weeks
Trial: 12544629
Drug: Progressive strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive strength training (3 times weekly, 2 sets of 6-8 repetitions at 70-80% of one repetition maximum)
Trial: 10364860
Drug: Sevoflurane 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane 8% in oxygen with rocuronium 0.3 mg.kg-1
Trial: 10364860
Drug: Sevoflurane 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane 8% in oxygen with rocuronium 0.45 mg.kg-1
Trial: 10364860
Drug: Sevoflurane 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane 8% in oxygen with rocuronium 0.6 mg.kg-1
Trial: 10364860
Drug: Propofol 2-3
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 2-3 mg.kg-1 with rocuronium 0.3 mg.kg-1
Trial: 10364860
Drug: Propofol 2-3
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 2-3 mg.kg-1 with rocuronium 0.45 mg.kg-1
Trial: 10364860
Drug: Propofol 2-3
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 2-3 mg.kg-1 with rocuronium 0.6 mg.kg-1
Trial: 10364860
Drug: Propofol 2-3
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 2-3 mg.kg-1 without muscle relaxant
Trial: 8659554
Drug: Comprehensive long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive long-term management program emphasizing inhaled corticosteroids and patient education (beclomethasone with a spacer, inhaled albuterol as needed, crisis prednisone).
Trial: 8659554
Drug: Comprehensive long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive long-term management program emphasizing inhaled corticosteroids and patient education.
Trial: 6362702
Drug: Brotizolam 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.50 mg and Flunitrazepam 2.0 mg
Trial: 27423107
Drug: 2% tofacitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% tofacitinib ointment twice daily
Trial: 27423107
Drug: Vehicle ointment
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle ointment twice daily
Trial: 24919385
Drug: Dimenhydrinate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate (40 mg) combined with Cinnarizine (25 mg)
Trial: 24919385
Drug: Promethazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (25 mg) combined with d-Amphetamine (10 mg)
Trial: 22132997
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and low-dose citrate (group H)
Trial: 17397097
Drug: Oxcarbazepine high
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine high (1500-1800 mg)
Trial: 17397097
Drug: Oxcarbazepine low
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine low (600-900 mg)
Trial: 10384064
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of terbutaline
Trial: 1986440
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (nifedipine SR + atenolol)
Trial: 30243187
Drug: Early anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early anticoagulation treatment
Trial: 20464170
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) three times a week during the initial four weeks of anti-TB treatment
Trial: 20464170
Drug: Anti-TB drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TB drugs only (Control)
Trial: 18788653
Drug: Sublingual zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual zolpidem tartrate 3.5 mg
Trial: 18788653
Drug: Sublingual zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual zolpidem tartrate 1.75 mg
Trial: 8823496
Drug: Oral NK611
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral NK611 at doses of 5, 10, and 20 mg/m2 on day 1, followed by a daily oral dose of 20 mg/m2 from day 4 to day 7 for a total of 85, 90, and 100 mg/m2.
Trial: 8823496
Drug: Intravenous NK611
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous NK611 (30-min infusion) at doses of 5, 10, and 20 mg/m2 on day 1.
Trial: 8823496
Drug: NK611 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK611 (oral and intravenous administration)
Trial: 1335640
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (0, 1 and 2 months schedule)
Trial: 1335640
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (0, 1 and 6 months schedule)
Trial: 6094422
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg sultamicillin, 12-hourly (series I)
Trial: 6094422
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg sultamicillin, 8-hourly (series II)
Trial: 25155134
Drug: Sufentanil sublingual
RxNorm normalized name: SUFentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil sublingual tablet system (SSTS) 15 mcg with a 20-minute lockout interval
Trial: 25155134
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia with morphine sulfate (IV PCA MS) 1 mg with a 6-minute lockout interval
Trial: 17457124
Drug: Sugammadex 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 8 mg/kg
Trial: 17457124
Drug: Sugammadex 4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4-8 mg/kg
Trial: 15088991
Drug: High sex-hormone-binding
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High sex-hormone-binding globulin levels
Trial: 15088991
Drug: Sex-hormone-binding globulin
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sex-hormone-binding globulin
Trial: 15088991
Drug: Sex-hormone-binding globulin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex-hormone-binding globulin, total and free testosterone, and estradiol
Trial: 7807484
Drug: Single, 1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, 1-g dose of cefazolin before clamping of the cord
Trial: 31013872
Drug: Live bifidobacteria
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live bifidobacteria (group L)
Trial: 31013872
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of groups H and L to group N
Trial: 17877887
Drug: Short-course, high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course, high-dose oral antiviral therapy (specific agents not detailed)
Trial: 17877887
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral antiviral agents (aciclovir, valaciclovir, famciclovir) with topical corticosteroids
Trial: 17877887
Drug: Prophylactic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic therapy for minimally invasive procedures
Trial: 15791515
Drug: Thermotherapy (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermotherapy (1 treatment of >or=1 consecutive application at 50 degrees C for 30 s)
Trial: 15791515
Drug: Intralesional sodium
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intralesional sodium stibogluconate (SSG) (5 injections of 2-5 mL every 5-7 days)
Trial: 15791515
Drug: Intramuscular sodium
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular sodium stibogluconate (SSG) (20 mg/kg daily for 21 days)
Trial: 7978470
Drug: Stress hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stress hormone infusion (epinephrine, cortisol, glucagon)
Trial: 28750232
Drug: Chair yoga
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chair yoga therapy (twice-weekly 20-min sessions for 12 weeks)
Trial: 28750232
Drug: Chair yoga
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chair yoga therapy
Trial: 25196993
Drug: Blosozumab 180
RxNorm normalized name: Blosozumab
DrugBank: Blosozumab (DB12560)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blosozumab 180 mg every 4 weeks (Q4W)
Trial: 25196993
Drug: Blosozumab (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blosozumab (highest dose group)
Trial: 23291970
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with ketorolac 30 mg IV and ketorolac plus paracetamol 650 mg orally every 6 h for 24 h (Group 1)
Trial: 23291970
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg IV and ketorolac plus paracetamol 650 mg orally every 6 h for 24 h (Group 3)
Trial: 21273183
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg daily orally until progression or inacceptable toxicity
Trial: 21273183
Drug: Intermittent erlotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent erlotinib and docetaxel (docetaxel 75 mg/m² on day 1 and erlotinib 150 mg orally on days 2‐16, recycled every 3 weeks up to 4 cycles, followed by erlotinib 150 mg daily until disease progression or inacceptable toxicity)
Trial: 19448377
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL sucrose 24% with pacifier
Trial: 19448377
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL sterile water with pacifier
Trial: 16933589
Drug: Quetiapine added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine added to usual treatment, attempted dosage of at least 400 mg daily.
Trial: 9578871
Drug: Tri‐adcortyl ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri‐adcortyl ointment (Squibb)
Trial: 7699846
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup (5 mg/kg)
Trial: 7699846
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup (10 mg/kg)
Trial: 7699846
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup
Trial: 2529299
Drug: Previous drug
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous drug treatment
Trial: 686922
Drug: COAP (vincristine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COAP (vincristine, prednisone, cytarabine 100 mg/sq m/day with cyclophosphamide)
Trial: 686922
Drug: DOAP (vincristine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOAP (vincristine, prednisone, cytarabine 100 mg/sq m/day with daunorubicin)
Trial: 686922
Drug: OAP (vincristine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAP (vincristine, prednisone, cytarabine 200 mg/sq m/day)
Trial: 686922
Drug: OAP (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAP (maintenance treatment)
Trial: 686922
Drug: COAP (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COAP (maintenance treatment)
Trial: 26590128
Drug: Niacin 100
RxNorm normalized name: niacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 100 mg
Trial: 21767340
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily detemir at 50, 65 or 80% of IV insulin requirements and aspart according to carbohydrate intake
Trial: 11756857
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy for 4 to 5 weeks
Trial: 11756857
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy for one year
Trial: 9008458
Drug: Verapamil 360
RxNorm normalized name: verapamil 360 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 360 mg
Trial: 9008458
Drug: Verapamil (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (all doses combined)
Trial: 29860040
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) 40 mg weekly
Trial: 12724679
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine infusion
Trial: 10227333
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray 0.03% plus beclomethasone dipropionate nasal spray
Trial: 10227333
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray 0.03% alone
Trial: 10227333
Drug: Combined active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined active therapy (ipratropium bromide plus beclomethasone)
Trial: 10227333
Drug: Vehicle (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (matching placebo nasal spray)
Trial: 2057268
Drug: Survanta (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survanta (100 mg of phospholipid/kg)
Trial: 30176281
Drug: Isoflavone supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplementation (100 mg/day)
Trial: 30176281
Drug: Placebo (starch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch, 100 mg/day)